In vivo pharmacological evaluation of a novel dual-target inhibitor and methylprednisolone as Alzheimer’s disease treatments
Background: Alzheimer’s disease (AD) is the most usual type of dementia, which often occurs in the late stage of life. As the population increases, the ageing problem has become more serious. Some researchers predicted that the number of AD patients would triple worldwide. Even though AD is a tough...
| Main Author: | |
|---|---|
| Format: | Thesis (University of Nottingham only) |
| Language: | English |
| Published: |
2023
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/72113/ |
| _version_ | 1848800716914688000 |
|---|---|
| author | Zhang, Bocheng |
| author_facet | Zhang, Bocheng |
| author_sort | Zhang, Bocheng |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Background: Alzheimer’s disease (AD) is the most usual type of dementia, which often occurs in the late stage of life. As the population increases, the ageing problem has become more serious. Some researchers predicted that the number of AD patients would triple worldwide. Even though AD is a tough challenging disease, there are still no effective drugs or therapies that could modify and overcome it.
Objective: This report illustrates the evaluation of a new inhibitor compound 19n (AChE + metal) and methylprednisolone (MP) on An acute Aβ toxic mouse model, to prove whether the tested compounds have anti-AD efficacy in vivo. Design and methods: An acute Aβ toxic mouse model was established and the short-term evaluation Y maze and long-term evaluation Morris water maze were applied to test whether the cognitive impairment was improved by 19n and MP. After testing, the brain samples were collected for measuring the levels of cytokines and inflammatory factors.
Results: The results of behavioural evaluation demonstrated that after both 19n and MP were treated, the time consumption of finding the hidden platform was decreased and the proportion of time spent in the quadrant containing the platform was elevated. Besides, no toxicity was observed in both two compounds at the described dosage.
Conclusion: Both 19n and MP could alleviate Aβ-induced cognitive decline. |
| first_indexed | 2025-11-14T20:55:59Z |
| format | Thesis (University of Nottingham only) |
| id | nottingham-72113 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-14T20:55:59Z |
| publishDate | 2023 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-721132023-04-13T10:20:34Z https://eprints.nottingham.ac.uk/72113/ In vivo pharmacological evaluation of a novel dual-target inhibitor and methylprednisolone as Alzheimer’s disease treatments Zhang, Bocheng Background: Alzheimer’s disease (AD) is the most usual type of dementia, which often occurs in the late stage of life. As the population increases, the ageing problem has become more serious. Some researchers predicted that the number of AD patients would triple worldwide. Even though AD is a tough challenging disease, there are still no effective drugs or therapies that could modify and overcome it. Objective: This report illustrates the evaluation of a new inhibitor compound 19n (AChE + metal) and methylprednisolone (MP) on An acute Aβ toxic mouse model, to prove whether the tested compounds have anti-AD efficacy in vivo. Design and methods: An acute Aβ toxic mouse model was established and the short-term evaluation Y maze and long-term evaluation Morris water maze were applied to test whether the cognitive impairment was improved by 19n and MP. After testing, the brain samples were collected for measuring the levels of cytokines and inflammatory factors. Results: The results of behavioural evaluation demonstrated that after both 19n and MP were treated, the time consumption of finding the hidden platform was decreased and the proportion of time spent in the quadrant containing the platform was elevated. Besides, no toxicity was observed in both two compounds at the described dosage. Conclusion: Both 19n and MP could alleviate Aβ-induced cognitive decline. 2023-03-15 Thesis (University of Nottingham only) NonPeerReviewed application/pdf en cc_by https://eprints.nottingham.ac.uk/72113/1/zhangbocheng%2014331661%20MRes.pdf Zhang, Bocheng (2023) In vivo pharmacological evaluation of a novel dual-target inhibitor and methylprednisolone as Alzheimer’s disease treatments. MRes thesis, University of Nottingham. Inhibitor compound; Anti-AD efficacy; Aβ-induced cognitive decline |
| spellingShingle | Inhibitor compound; Anti-AD efficacy; Aβ-induced cognitive decline Zhang, Bocheng In vivo pharmacological evaluation of a novel dual-target inhibitor and methylprednisolone as Alzheimer’s disease treatments |
| title | In vivo pharmacological evaluation of a novel dual-target inhibitor and methylprednisolone as Alzheimer’s disease treatments |
| title_full | In vivo pharmacological evaluation of a novel dual-target inhibitor and methylprednisolone as Alzheimer’s disease treatments |
| title_fullStr | In vivo pharmacological evaluation of a novel dual-target inhibitor and methylprednisolone as Alzheimer’s disease treatments |
| title_full_unstemmed | In vivo pharmacological evaluation of a novel dual-target inhibitor and methylprednisolone as Alzheimer’s disease treatments |
| title_short | In vivo pharmacological evaluation of a novel dual-target inhibitor and methylprednisolone as Alzheimer’s disease treatments |
| title_sort | in vivo pharmacological evaluation of a novel dual-target inhibitor and methylprednisolone as alzheimer’s disease treatments |
| topic | Inhibitor compound; Anti-AD efficacy; Aβ-induced cognitive decline |
| url | https://eprints.nottingham.ac.uk/72113/ |